

TriNetX Oncology

Real-World Evidence in Oncology & Hematology

pLGG Epidemiology and Treatment Patterns Study

Pediatric Low-Grade Glioma | Multinational Study | DE · UK · FR · NL

DISTINCTION: TriNetX pLGG Epidemiology and Treatment Patterns Study vs. Adelphi Burden of Illness pLGG Study

	TriNetX Oncology — pLGG Epidemiology and Treatment Patterns Study	Adelphi — Burden of Illness pLGG Study
Primary goal	Collect and publish the epidemiology of pLGG and real-world treatment patterns for patients with pLGG who are treated with systemic therapy	Quantify disease burden, quality of life, healthcare resource utilization of patients with pLGG
Data level	Aggregated (no patient data)	Patient-level data collection
Ethics / Consent	Not required (aggregated methodology)	Patient consent

pLGG Epidemiology and Treatment Patterns Study — AT A GLANCE

Compensation of **800€** for the completed questionnaire after quality control and **option of co-authorship** in publication of results

Disease area: Pediatric Low-Grade Glioma (pLGG)
Study type: Retrospective observational study
Countries: Germany, United Kingdom, France, Netherlands
Design: Chart Review
Patient data: None – summary of aggregated patient level data
Status: Active

STUDY OBJECTIVES

- ▶ Describe real-world pLGG treatment patterns across centers in Germany, UK, France, and Netherlands including systemic treatments used by lines of therapy and treatment sequencing
- ▶ Identify gaps between guideline recommendations and clinical practice
- ▶ Improve understanding of pLGG treatment to support better patient care and clinical decision-making
- ▶ Describe the incidence of low-grade glioma overall and treated incidence of low-grade glioma among pediatric patients with a BRAF-altered tumor in Europe

DATA PRIVACY & ETHICS

- ▶ No access to patient-level records at your site
- ▶ Your institution's identity remains protected from third parties
- ▶ No ethics committee vote or patient consent required (aggregated data methodology)

TriNetX Oncology - WHO WE ARE

TriNetX Oncology is an innovative, internationally active real-world evidence institute with extensive experience in oncology and hematology.

- ▶ 30+ years collecting and analyzing Real-World Data in oncology & hematology
- ▶ Results published at major international congresses and peer-reviewed journals
- ▶ Expertise in comparing treatment reality vs. clinical trial outcomes
- ▶ Data collection in Europa: Germany, France, United Kingdom, Spain
- ▶ Strong focus on oncology and hematology

Contact Details Project Team

- Constanze Kriegel
Constanze.kriegel@trinetx.com
+49 761-38399404
- Maria Friese
Maria.friese@trinetx.com
+49 761-383994-23
- General point of Contact
Oncology@trinetx.com
+49 761-383994-0